Geneos Therapeutics

Geneos Therapeutics

  • Founded: 2019
  • Location: Plymouth Meeting, PA
  • Employee range: 1 - 10
  • Clinical stage: Clin2
  • Therapy area: Hepatocellular carcinoma
  • Drug types: ONC
  • Lead product: GT-30
  • Product link:
  • Funding: $5M A3 Apr 2023; $17M A2 Mar 2022; $12M A1 Mar 2021; $10.4M Nov 2020; $10.5M Feb 2019
  • Investors: 3B Future Health Fund

job board

Short description:

Plasmid-based Neoantigen-targeted Cancer Therapies

Drug notes:

GT-31 Clin0/Clin1 hepatocellular carcinoma; GT-10 Clin1 glioblastoma; GT-20 Clin1 glioblastoma

Long description:

Geneos Therapeutics is creating personalized immunotherapies designed to treat cancer. Neoantigens refer to novel peptides that can be recognised by the immune system to build an immune response. They arise in cancer cells following mutations. Geneos is using their platform to rapidly deploy a therapeutic construct that includes all targetable neoantigens and offer the immune system an opportunity to attack cancer via all present neoantigens. The process begins by sequencing a patient’s tumor DNA to first identify the neoantigens and ends with a DNA plasmid drug product that can be used to dose patients. Geneos’ most advanced program using their approach is for advanced hepatocellular carcinoma.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy